文献速递复苏、休克与脓毒症心脑血管急症呼吸衰竭与机械通气

covid-19后深静脉血栓、肺栓塞和出血的风险:全国自我对照病例系列和匹配队列研究

Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study.
PubMed 文献 · BMJ · 2022-04-06
一句话结论covid-19是深静脉血栓、肺栓塞和出血的风险因素,肺栓塞风险在感染后第二周最高(发生率比46.40)。

该研究基于瑞典全国登记数据,纳入1 057 174例SARS-CoV-2阳性者,按年龄、性别和居住县匹配4 076 342名对照。采用自我对照病例系列和条件Poisson回归计算发生率比,匹配队列研究计算风险比。结果显示covid-19后深静脉血栓风险升高持续70天、肺栓塞110天、出血60天;感染后1-30天肺栓塞风险比高达33.05。作者认为covid-19是静脉血栓栓塞和出血的风险因素,可能影响covid-19后静脉血栓栓塞的诊断和预防策略建议。

要点

  • covid-19后第一周肺栓塞发生率比36.17(95%CI 31.55-41.47),第二周升至46.40(40.61-53.02)。
  • 感染后1-30天,深静脉血栓风险比4.98(4.96-5.01),肺栓塞33.05(32.8-33.3),出血1.88(1.71-2.07)。
  • 风险升高持续时间:深静脉血栓70天、肺栓塞110天、出血60天(与对照期比较)。
  • 重症covid-19患者风险比最高,且瑞典第一波疫情高于第二和第三波。
  • 感染后1-30天绝对风险:深静脉血栓0.039%(401例事件),肺栓塞0.17%(1761例事件),出血0.101%(1002例事件)。

适用人群与场景

  • 2020年2月1日至2021年5月25日在瑞典SARS-CoV-2检测阳性者1 057 174人,按年龄、性别和居住县匹配4 076 342名对照。

研究设计与关键结果

  • 研究设计为自我对照病例系列和匹配队列研究,使用瑞典全国登记数据。
  • 与对照期相比,covid-19后深静脉血栓发生率比显著升高持续70天,肺栓塞110天,出血60天。
  • 感染后第一周肺栓塞发生率比36.17(95%CI 31.55-41.47),第二周46.40(40.61-53.02)。
  • 感染后1-30天发生率比:深静脉血栓5.90(5.12-6.80),肺栓塞31.59(27.99-35.63),出血2.48(2.30-2.68)。
  • 调整潜在混杂因素(合并症、癌症、手术、长期抗凝治疗、既往静脉血栓栓塞或既往出血事件)后,感染后1-30天风险比:深静脉血栓4.98(4.96-5.01),肺栓塞33.05(32.8-33.3),出血1.88(1.71-2.07)。
  • 风险比在重症covid-19患者中最高,在瑞典第一波疫情期间高于第二和第三波。
  • 同期covid-19患者绝对风险:深静脉血栓0.039%(401例事件),肺栓塞0.17%(1761例事件),出血0.101%(1002例事件)。

证据类型、等级与局限

  • 证据类型:全国自我对照病例系列和匹配队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为covid-19是深静脉血栓、肺栓塞和出血的风险因素。
  • 作者认为这些结果可能影响covid-19后静脉血栓栓塞的诊断和预防策略建议。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To quantify the risk of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19.

DESIGN: Self-controlled case series and matched cohort study.

SETTING: National registries in Sweden.

PARTICIPANTS: 1 057 174 people who tested positive for SARS-CoV-2 between 1 February 2020 and 25 May 2021 in Sweden, matched on age, sex, and county of residence to 4 076 342 control participants.

MAIN OUTCOMES MEASURES: Self-controlled case series and conditional Poisson regression were used to determine the incidence rate ratio and risk ratio with corresponding 95% confidence intervals for a first deep vein thrombosis, pulmonary embolism, or bleeding event. In the self-controlled case series, the incidence rate ratios for first time outcomes after covid-19 were determined using set time intervals and the spline model. The risk ratios for first time and all events were determined during days 1-30 after covid-19 or index date using the matched cohort study, and adjusting for potential confounders (comorbidities, cancer, surgery, long term anticoagulation treatment, previous venous thromboembolism, or previous bleeding event).

RESULTS: Compared with the control period, incidence rate ratios were significantly increased 70 days after covid-19 for deep vein thrombosis, 110 days for pulmonary embolism, and 60 days for bleeding. In particular, incidence rate ratios for a first pulmonary embolism were 36.17 (95% confidence interval 31.55 to 41.47) during the first week after covid-19 and 46.40 (40.61 to 53.02) during the second week. Incidence rate ratios during days 1-30 after covid-19 were 5.90 (5.12 to 6.80) for deep vein thrombosis, 31.59 (27.99 to 35.63) for pulmonary embolism, and 2.48 (2.30 to 2.68) for bleeding. Similarly, the risk ratios during days 1-30 after covid-19 were 4.98 (4.96 to 5.01) for deep vein thrombosis, 33.05 (32.8 to 33.3) for pulmonary embolism, and 1.88 (1.71 to 2.07) for bleeding, after adjusting for the effect of potential confounders. The rate ratios were highest in patients with critical covid-19 and highest during the first pandemic wave in Sweden compared with the second and third waves. In the same period, the absolute risk among patients with covid-19 was 0.039% (401 events) for deep vein thrombosis, 0.17% (1761 events) for pulmonary embolism, and 0.101% (1002 events) for bleeding.

CONCLUSIONS: The findings of this study suggest that covid-19 is a risk factor for deep vein thrombosis, pulmonary embolism, and bleeding. These results could impact recommendations on diagnostic and prophylactic strategies against venous thromboembolism after covid-19.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Katsoularis I, Fonseca-Rodríguez O, Farrington P, et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ. 2022. PMID: 35387772. doi:10.1136/bmj-2021-069590

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。